SynthesisApplied health economics and health policy2021
National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India.
Synthesis in Applied health economics and health policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Burden of Influenza and Cost-Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India.Influenza and other respiratory viruses · 2026Article
- Budget impact analysis of a vision center-based community eye health program in an underserved urban slum in India.Indian journal of ophthalmology · 2026Article
- A Mixed-Methods Assessment of India's Health Technology Assessment Ecosystem.Applied health economics and health policy · 2026Article
- Insights and implications: an analysis of the studies undertaken by Health Technology Assessment in India (HTAIn).Health research policy and systems · 2025Article
- Setting priorities for healthcare interventions in Indonesia: a comprehensive conceptual framework.International journal for equity in health · 2025Review
- Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran.BMC health services research · 2025Article
- Methods and Practical Considerations for Conducting Budget Impact Analysis for Non-Pharmaceutical Interventions.Applied health economics and health policy · 2025Review
- Economic assessment of potential changes to essential medicines for diabetes in Uganda.PloS one · 2025Article
- Article
- Development of the Indian Reference Case for undertaking economic evaluation for health technology assessment.The Lancet regional health. Southeast Asia · 2023Review
- Cost-effectiveness of population-based screening for oral cancer in India: an economic modelling study.The Lancet regional health. Southeast Asia · 2023Article
- Budget impact analysis of breast cancer medications: a systematic review.Journal of pharmaceutical policy and practice · 2022Review
- Cost-effectiveness analysis of 'test and treat' policy for antiretroviral therapy among heterosexual HIV population in India.The Indian journal of medical research · 2022Article
- Adherence to Consolidated Health Economic Evaluation Reporting Standards guidelines for published pharmacoeconomic studies in PubMed-indexed medical journals over a year (2021-2022).Perspectives in clinical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveOur paper aims to present Budget Impact Analysis (BIA) guidelines for health technology assessment (HTA) in India. METHODOLOGY: A Systematic Literature Review (SLR) was conducted to retrieve information on existing BIA guidelines internationally. The initial set of principles for India were put together based on an interactive process between authors, taking into consideration the existing evidence on BIA and features of Indian healthcare system. These were reviewed by Technical Appraisal Committee (TAC) of Health Technology Assessment in India (HTAIn) for their inputs. Three rounds of consultations were held before finalising the guidelines. Finally, user feedback on the draft guidelines was obtained from the policy makers and programme managers involved in the budgeting decisions.
resultsWe recommend a payer's perspective, which will include both a multi-payer (depicting the current situation in India) and a single-payer scenario (which reflects a futuristic universal health care situation). A time horizon of 1-4 years is recommended. For estimation of eligible population, a top-down approach is considered appropriate. The future and current mix of interventions should be analysed for different utilisation and coverage patterns. We do not recommend discounting; however, inflation adjustments should be performed. The presentation of results should include total and disaggregated results, segregated year-wise throughout the chosen time horizon, as well as segregated by the type of resources. Deterministic sensitivity analysis and scenario analysis are recommended to address uncertainty.
conclusionOur recommendations, which are tailored for the Indian healthcare and financing context, aim to promote consistency and transparency in the conduct as well as reporting of the BIA. BIA should be used along with evidence from economic evaluation for decision making, and not as a substitute to evidence on value for money.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.